Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | PTEN L194fs |
Gene Variant Detail | |
Relevant Treatment Approaches | Akt Inhibitor (Pan) Akt1 Inhibitor Akt2 Inhibitor PI3K Inhibitor (Pan) PIK3CB inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
PTEN L194fs | thyroid cancer | predicted - sensitive | Ipilimumab + Nivolumab + Temsirolimus | Case Reports/Case Series | Actionable | In a clinical case study, the addition of Torisel (temsirolimus) to the combination treatment of Yervoy (ipilimumab) and Opdivo (nivolumab) resulted in a partial response with a decrease in target lesion size in a patient with poorly differentiated thyroid cancer harboring PTEN L194fs, along with TP53 F270S, who remained on treatment for 6 months (PMID: 38356955). | 38356955 |